Pfizer Inc. $PFE Shares Purchased by Payden & Rygel

Payden & Rygel grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 53,868.4% in the fourth quarter, HoldingsChannel reports. The fund owned 205,080 shares of the biopharmaceutical company’s stock after buying an additional 204,700 shares during the period. Payden & Rygel’s holdings in Pfizer were worth $5,106,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the 3rd quarter worth about $29,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1%

NYSE PFE opened at $25.31 on Tuesday. The firm’s 50 day moving average price is $26.96 and its two-hundred day moving average price is $26.20. The stock has a market cap of $144.22 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. Pfizer Inc. has a twelve month low of $22.64 and a twelve month high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the firm posted $0.92 earnings per share. Pfizer’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Bank of America cut their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Royal Bank Of Canada reiterated an “underperform” rating and set a $25.00 price target on shares of Pfizer in a research report on Monday, April 20th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research note on Monday, March 2nd. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.